Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Temozolomide

Temozolomide Am J Cancer 2002; 1 (1): 55-80 ADIS DRUG EVALUATION 1175-6357/01/0001-0055/$25.00/0 © Adis International Limited. All rights reserved. A Review of its Use in the Treatment of Malignant Gliomas, Malignant Melanoma and Other Advanced Cancers Malcolm J.M. Darkes, Greg L. Plosker and Blair Jarvis Adis International Inc., Langhorne, Pennsylvania, USA Various sections of the manuscript reviewed by: S. D’Atri, Instituto Dermopatico Dell’Immacolata, Rome, Italy; H.S. Friedman, Duke University, Departments of Surgery, Medicine and Pediatrics, Durham, North Carolina, USA; L.A. Hammond, Cancer Therapy and Research Center, The Institute for Drug Development, San Antonio, Texas, USA; M.R. Middleton, Churchill Hospital, ICRF Medical Oncology Unit, Oxford, United Kingdom; J.M. Reid, Mayo Clinic, Department of Oncology, Rochester, Minnesota, USA; K. Warren, National Institutes of Health, Bethesda, Maryland, USA. Data Selection Sources: Medical literature published in any language since 1980 on temozolomide, identified using Medline and EMBASE, supplemented by AdisBase (a proprietary database of Adis International). Additional references were identified from the reference lists of published articles. Bibliographic information, including contributory unpublished data, was also requested from the company developing the drug. Search strategy: Medline search terms were ‘temozolomide’. EMBASE search terms were ‘temozolomide’. AdisBase search terms were ‘temozolomide’ or ‘CCRG 81045’. Searches were http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cancer Springer Journals

Loading next page...
 
/lp/springer-journals/temozolomide-DSfU7egSJ3
Publisher
Springer Journals
Copyright
Copyright © 2002 by Adis International Limited
Subject
Pharmacy; Pharmacy
ISSN
1175-6357
DOI
10.2165/00024669-200201010-00006
Publisher site
See Article on Publisher Site

Abstract

Am J Cancer 2002; 1 (1): 55-80 ADIS DRUG EVALUATION 1175-6357/01/0001-0055/$25.00/0 © Adis International Limited. All rights reserved. A Review of its Use in the Treatment of Malignant Gliomas, Malignant Melanoma and Other Advanced Cancers Malcolm J.M. Darkes, Greg L. Plosker and Blair Jarvis Adis International Inc., Langhorne, Pennsylvania, USA Various sections of the manuscript reviewed by: S. D’Atri, Instituto Dermopatico Dell’Immacolata, Rome, Italy; H.S. Friedman, Duke University, Departments of Surgery, Medicine and Pediatrics, Durham, North Carolina, USA; L.A. Hammond, Cancer Therapy and Research Center, The Institute for Drug Development, San Antonio, Texas, USA; M.R. Middleton, Churchill Hospital, ICRF Medical Oncology Unit, Oxford, United Kingdom; J.M. Reid, Mayo Clinic, Department of Oncology, Rochester, Minnesota, USA; K. Warren, National Institutes of Health, Bethesda, Maryland, USA. Data Selection Sources: Medical literature published in any language since 1980 on temozolomide, identified using Medline and EMBASE, supplemented by AdisBase (a proprietary database of Adis International). Additional references were identified from the reference lists of published articles. Bibliographic information, including contributory unpublished data, was also requested from the company developing the drug. Search strategy: Medline search terms were ‘temozolomide’. EMBASE search terms were ‘temozolomide’. AdisBase search terms were ‘temozolomide’ or ‘CCRG 81045’. Searches were

Journal

American Journal of CancerSpringer Journals

Published: Aug 9, 2012

References